A new Medicare program is making certain GLP-1 weight-loss medications available for $50 per month—but not everyone with Medicare qualifies. Here’s who may be eligible, which drugs are included, and what you need to know before asking your doctor.
GLP-1 medications have become one of the biggest stories in U.S. healthcare, particularly for people looking for prescription treatment for weight management.
Now, Medicare beneficiaries have a new option.
Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge, a temporary demonstration that can provide certain eligible Medicare Part D beneficiaries with covered GLP-1 medications for a $50 monthly copay. The program is currently scheduled to continue through December 31, 2027.
But there is an important catch.
Having Medicare alone does not automatically qualify you for the $50 option.
There are specific Medicare coverage, medical and prescription-history requirements.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a CMS demonstration designed to provide eligible Medicare beneficiaries with access to certain GLP-1 medications when they are prescribed specifically for reducing excess body weight or maintaining weight reduction.
The program operates outside the normal Medicare Part D benefit and payment flow.
For an eligible beneficiary, the cost is $50 per month, regardless of income. The $50 payment does not count toward the beneficiary’s Part D deductible or annual out-of-pocket limit.
The program is available nationwide.
However, eligibility depends on several requirements.
Who Can Get Medicare GLP-1 Coverage for $50?
To potentially qualify for the Medicare GLP-1 Bridge, you generally need to meet all of the program’s requirements.
You Need Medicare Part D Drug Coverage
You must have Medicare prescription drug coverage through an eligible Part D arrangement.
This can include:
- A standalone Medicare Prescription Drug Plan
- A Medicare Advantage plan with prescription drug coverage
- Certain other eligible Part D arrangements
CMS says the program is available nationwide, but certain Medicare plan types are excluded unless the beneficiary also has an eligible standalone Part D plan.
So simply having Original Medicare Part A and Part B isn’t enough.
Part D drug coverage is an important part of eligibility.
You Must Be at Least 18
The Medicare GLP-1 Bridge is available only to people who are 18 or older.
But age alone doesn’t qualify someone.
You must also meet the program’s clinical criteria related to BMI and certain health conditions.
Your BMI and Health History Matter
CMS has established specific clinical pathways for eligibility.
A beneficiary may qualify if they meet one of these categories:
| Eligibility pathway | Requirement |
|---|---|
| Higher BMI | Age 18+ and BMI of 35 or higher |
| BMI + certain conditions | Age 18+ and BMI of 30 or higher, plus certain heart failure, uncontrolled hypertension, or stage 3a+ chronic kidney disease |
| BMI + other conditions | Age 18+ and BMI of 27 or higher, plus prediabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease |
These criteria are assessed in connection with the initiation of GLP-1 therapy. CMS says the prescribing provider must submit a prior authorization request attesting that the beneficiary meets the applicable requirements.
BMI 35 or Higher
If you are at least 18 and have a BMI of 35 or higher, you may meet one of the clinical eligibility pathways.
BMI 30 or Higher Plus Certain Conditions
A person with a BMI of at least 30 may qualify if they also have one of the specified conditions, including:
- Heart failure with preserved ejection fraction
- Uncontrolled hypertension
- Chronic kidney disease stage 3a or higher
CMS defines uncontrolled hypertension for this program using specific criteria, so simply having a history of high blood pressure does not necessarily satisfy the requirement.
BMI 27 or Higher Plus Certain Conditions
A person with a BMI of at least 27 may qualify when they also have certain conditions or medical history, including:
- Prediabetes
- Previous heart attack
- Previous stroke
- Symptomatic peripheral artery disease
Again, the program has specific clinical criteria that must be verified through the prior authorization process.
Which GLP-1 Drugs Are Covered?
The Medicare GLP-1 Bridge currently covers certain medications when they are used for weight management.
CMS lists:
- Foundayo
- Wegovy
- Zepbound KwikPen
There is an important formulation restriction for Zepbound.
The program covers the Zepbound KwikPen, but not the single-dose Zepbound pens or single-dose vials under the Bridge.
The list can be updated by CMS, so consumers should check the current Medicare information before assuming a particular medication or formulation qualifies.
The $50 Price Has an Important Catch
The headline number is simple:
$50 per month.
But that $50 does not work exactly like a normal Medicare Part D copay.
The Medicare GLP-1 Bridge operates outside the Part D benefit.
That means:
- The Part D deductible does not apply.
- The $50 does not count toward your Part D annual out-of-pocket costs.
- The $50 does not qualify for the Medicare Prescription Payment Plan.
- Low-income subsidy assistance does not reduce the $50 Bridge copay.
- Coupons and discount programs cannot be applied to Bridge claims.
So someone shouldn’t assume that Extra Help or another Medicare drug benefit will reduce the $50 amount.
Who Does NOT Qualify for the $50 GLP-1 Bridge?
This is where many Medicare beneficiaries could misunderstand the program.
You Already Received a GLP-1 Through Part D
If you have already received a GLP-1 medication paid for by your Medicare Part D plan during 2026, you generally aren’t eligible to move that prescription to the Medicare GLP-1 Bridge.
CMS says beneficiaries who have received a GLP-1 through Part D in 2026 are not eligible for the Bridge.
If your Part D plan already covers your GLP-1 for an eligible medical indication, you should continue obtaining it through that plan rather than attempting to use the Bridge.
You Have Certain Conditions That May Already Qualify for Part D Coverage
The Bridge is designed specifically for weight-management use.
CMS states that people with certain conditions—including type 2 diabetes, moderate-to-severe obstructive sleep apnea, and specified fatty liver disease indications—may have access to GLP-1 coverage through their existing Part D benefit instead.
Those beneficiaries aren’t eligible to use the Bridge simply because they meet its BMI criteria.
This distinction is extremely important.
The $50 Bridge isn’t a universal Medicare discount for every GLP-1 prescription.
Do You Need Prior Authorization?
Yes.
A healthcare provider must submit a prior authorization request and attest that the beneficiary meets the applicable clinical requirements.
After the first fill is approved, CMS says subsequent refills generally do not require a new prior authorization unless the beneficiary switches to a different covered GLP-1 medication.
That means the process isn’t simply:
Medicare card → pharmacy → $50 prescription.
There is an eligibility and authorization process in between.
What If Your BMI Has Changed?
This is another detail consumers may miss.
CMS says the relevant clinical criteria are connected to the time the beneficiary initiated GLP-1 therapy.
For example, a person could have started treatment when their BMI was 37 and later have a BMI of 34 when the Bridge authorization is requested. CMS says the provider can attest to the applicable BMI criterion at the time therapy was initiated, if the other requirements are met.
Your doctor and the authorization process determine whether the documentation satisfies the program requirements.
Does the $50 Count Toward Your Medicare Out-of-Pocket Maximum?
No.
This is one of the most important details about the Medicare GLP-1 Bridge.
Because the Bridge operates outside the Part D benefit, the $50 monthly payment does not count toward your Part D deductible or annual out-of-pocket limit.
For consumers comparing medication costs, this distinction can matter.
How Long Will the Medicare GLP-1 Bridge Last?
The program began July 1, 2026.
CMS currently says the Medicare GLP-1 Bridge will run through December 31, 2027.
CMS also says the Bridge was extended through the end of 2027 after the planned BALANCE Model did not launch in 2027, allowing CMS to collect additional data on GLP-1 utilization.
That means beneficiaries shouldn’t assume the $50 arrangement is a permanent Medicare benefit.
How to Find Out If You Qualify
If you’re interested in the Medicare GLP-1 Bridge, start with your healthcare provider.
You can ask:
“Do I meet the Medicare GLP-1 Bridge requirements for weight-management treatment?”
You should also confirm:
- Whether you have eligible Medicare Part D coverage.
- Whether your current Medicare plan is an eligible plan type.
- Whether you meet the BMI and medical-history requirements.
- Whether you have previously received a GLP-1 through Part D in 2026.
- Which covered medication your provider believes is appropriate.
- Whether prior authorization is required.
- Whether your pharmacy can process the Bridge prescription.
Medicare also directs beneficiaries to Medicare.gov/glp1bridge and 1-800-MEDICARE for program information.
Medicare GLP-1 Coverage 2026: What Consumers Should Remember
The new $50 option is significant, but it isn’t available to every Medicare beneficiary.
The basic picture is:
Medicare Part D → Eligible plan type → Weight-management use → Clinical criteria → Prior authorization → Covered GLP-1 → $50 monthly copay
Missing one of the key eligibility requirements can mean the Bridge isn’t available.
And if your GLP-1 is already covered by Medicare Part D for an eligible medical condition, the Bridge generally isn’t the route you should use.
Final Takeaway
The Medicare GLP-1 Bridge gives certain eligible Medicare Part D beneficiaries access to specific GLP-1 medications for $50 per month.
The program began July 1, 2026, and is currently scheduled to continue through December 31, 2027.
But the $50 price comes with eligibility rules.
You generally need eligible Part D coverage, must meet the program’s age and clinical criteria, and must be seeking the medication for the qualifying weight-management indication. Prior authorization is also part of the process.
The safest approach is to check your specific Medicare coverage and speak with your healthcare provider before changing or starting prescription treatment.
Frequently Asked Questions
Is Medicare really offering GLP-1 drugs for $50 a month in 2026?
Yes. Eligible beneficiaries can receive certain GLP-1 medications through the Medicare GLP-1 Bridge for a $50 monthly copay.
Who qualifies for the $50 Medicare GLP-1 option?
Eligible Medicare Part D beneficiaries must meet the program’s plan, age, clinical and prescription-history requirements. BMI thresholds and certain health conditions are part of the eligibility criteria.
Which GLP-1 drugs are included?
CMS currently lists Foundayo, Wegovy and Zepbound KwikPen for qualifying weight-management use. Certain Zepbound formulations are excluded.
Does the $50 copay count toward the Medicare Part D out-of-pocket limit?
No. The Bridge operates outside the Part D benefit, so the $50 copay does not count toward the Part D deductible or annual out-of-pocket limit.
Can someone with diabetes use the $50 GLP-1 Bridge?
The Bridge is intended for qualifying weight-management use. CMS says people with type 2 diabetes and certain other conditions may instead have access to GLP-1 treatment through their existing Part D benefit and therefore are not eligible for the Bridge for that purpose.
Is the Medicare GLP-1 Bridge permanent?
No. It is a temporary CMS demonstration currently scheduled to operate through December 31, 2027.
Where can I check my eligibility?
Medicare directs beneficiaries to its GLP-1 Bridge information page or 1-800-MEDICARE for assistance with eligibility and program questions.
Important: Medicare coverage rules and the list of eligible products can change. Verify your current eligibility and medication coverage with Medicare, your Part D plan, and your healthcare provider before making a treatment or insurance decision.